Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications
Melanoma is the most aggressive type of skin cancer that arises from melanocytes, the pigment-producing cells of the body. The seminal discovery that approximately 40-50% of melanomas are driven by BRAFV600 mutations and advances in tumour immunology have paved the way to targeted and immune therapies that have significantly improved response rates and outcome [1]. However, reliable diagnoses are required to provide the best treatment strategy. The diagnosis of primary melanoma, based on well-established morpho-phenotypic features, is usually straightforward [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Daniela Massi, Daniela Mihic-Probst, Dirk Schadendorf, Reinhard Dummer, Mario Mandal à Tags: Tumour Review Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Genetics | Melanoma | Skin | Skin Cancer